Hookipa Pharma Inc. products

Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating.  Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology.  Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease.

The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated delivery platform based on arenaviruses, a family of naturally-occurring viruses.

Our proprietary replicating technology was designed to provide the beneficial properties of our non-replicating technology but to induce an even more robust immune response. Unlike naturally occurring arenaviruses which have two genomic segments, our replicating constructs were engineered to have three segments in order to allow for the introduction of genomic space in which to insert additional target antigens of choice. As a result of the larger genome the virus’ ability to replicate is reduced (attenuated).